Cutting-Edge Liquid Biopsy
Transforming Precision Oncology through early, actionable insights
At mDETECT, we are redefining how cancer is monitored. By harnessing the power of epigenetics and circulating tumor DNA, our next-generation liquid biopsy platform gives oncologists precise, quantitative data on tumor burden. Our goal is to help clinicians with faster treatment decisions in a setting where every week counts.
​​​
Our Mission: To eliminate the uncertainty in cancer treatment by delivering accessible, rapid, and accurate liquid biopsy solutions that extend and improve lives.
The Challenge & Our Solution
The Gap in Current Cancer Monitoring
For patients undergoing treatment for metastatic and solid tumors, waiting months for conventional CT or MRI scans to prove whether a therapy is working can result in lost time, unnecessary drug toxicity, and delayed pivots to effective alternatives. Traditional blood-based tests that rely on specific genetic mutations often miss disease progression because tumors evolve and vary drastically between individuals.
The mDETECT Epigenetic Advantage
The mDETECT tests analyze tumor-specific DNA methylation signatures, a type of epigenetic modification, that is present across widespread cancer types.
​
Our targeted Next-Generation Sequencing (NGS) assay measures subtle shifts in circulating tumor DNA from a simple, routine blood draw. This allows clinicians to assess therapeutic response within weeks of treatment initiation, long before changes appear on radiological imaging.
From Research Bench to Clinical Impact
Spun out from research at Queen’s University in Kingston, Ontario, mDETECT was founded to bridge the gap between epigenetic science and clinical care.
​
Backed by seed funding, competitive research grants, and clinical partnerships, our team is driving multi-center validation trials to bring methylation-based monitoring into routine cancer care worldwide.
​
Ready to collaborate? Whether you are a clinical researcher, biotech partner, or health system leader, reach out to learn how mDETECT is shaping the future of therapeutic monitoring.
Filling gaps in your cancer care
The mDETECT Difference
Tracks universal DNA methylation patterns rather than patient-specific mutations
Ultra-low sample requirements; 2mL of serum/plasma per patients is needed
Rapid turnaround times with results in days
Clinical & Economic Impact